Every year, OHE sponsors a lecture by an eminent economist or clinician that addresses an important current issue. This year we are pleased to welcome Prof. Sir Michael Rawlins, who argues against reliance on randomized clinical trials as the "gold standard", instead urging a more pragmatic approach.
Sir Michael's experience - as a clinician, chair of the Committee on Safety of Medicines, and chair of NICE -- uniquely qualifies him to address these issues.
July 2013 editor's note: click here for OHE's publication based on this lecture.
Posted in Drug Development/R&D, General, NICE, Pricing and Reimbursement | Tagged 50th Anniversary, annual lecture